Share this article on:

Abstract 21: Whole-Proteome Analysis and Immunohistochemical Staining of Craniosynostotic Tissue Suggest a Link between Inflammatory Signaling and Osteoclast Activation in Cranial Suture Patency

Plastic and Reconstructive Surgery – Global Open: April 2016 - Volume 4 - Issue 4S - p 12
doi: 10.1097/01.GOX.0000488891.87251.bf
PRS AAPS Oral Proofs 2016

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Sarah M. Lyon, BA,* Jixing Ye, MS,* Michael Januszyk, MD, PhD,† Anoop Mayampurath, PhD,* Darrel J. Waggoner, MD,* David M. Frim, MD, PhD,* Tong-Chuan He, MD, PhD,* Russell R. Reid, MD, PhD*

From the *The University of Chicago, Chicago, Ill.; and †Stanford University, Stanford, Calif.

PURPOSE: Nonsyndromic craniosynostosis can be associated with developmental delay, hearing and visual impairment, and craniofacial asymmetries. Despite its relatively high prevalence, the pathophysiology remains poorly understood. We previously identified proteins differentially expressed in patent and fused cranial sutures by comparing their respective proteomes. Here, we analyze these proteins using immunohistochemistry.

METHODS: Fused and patent suture samples were obtained from 5 craniosynostotic patients (age, 3–12 months) undergoing cranial vault reconstruction at a single academic medical center. Protein was extracted from samples and interrogated using mass spectrometry. Differential protein expression was determined using the maximum likelihood-based G-test with q value cutoffs of 0.5 after correction for multiple hypothesis testing. Immunolocalization of lead protein candidates was performed in patent and fused sutures.

RESULTS: Proteins differentially expressed in patent versus fused sutures included the proinflammatory mediator FMOD and multiple collagen proteins including Col6A1. Maximum likelihood-based G-test suggested that Col6A1 and FMOD are highly expressed in patent sutures compared with fused. Immunohistochemical staining of sutures demonstrated Col6A1 up-regulation in patent sutures (A) compared with fused (B).

CONCLUSIONS: These results suggest that Col6A1 may aid in the regulation of suture patency. Previous reports linking Col6A1 with the RANK-RANKL osteoclast activation pathway in rheumatoid arthritis suggest a link between osteoclast and inflammatory signaling inactivation and premature cranial suture fusion. These preliminary findings may have considerable therapeutic implications, although additional validation studies are required.

© 2016 American Society of Plastic Surgeons